STEVENS-JOHNSON SYNDROME INDUCED BY MAGNESIUM SULFATE: A CLINICAL CASE

2025

Closed access Metadata (CSL-JSON)
DOI 10.53511/pharmkaz.2025.3.16
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

This article presents a clinical case of the development of Stevens–Johnson syndrome in a patient following intravenous administration of magnesium sulfate at therapeutic doses, which gradually led to delayed sensitization of the body. This clinical case demonstrates the characteristics of the disease progression, the dynamics of symptom escalation, and the complexity of treatment. The importance of early diagnosis and timely initiation of therapy in such severe cutaneous allergic reactions is emphasized. A written voluntary informed consent has been obtained from the patient to publish a description of the clinical case and the publication of photographic materials (protocol №000001595). Оbjective: The aim of this study is to present a clinical case of Stevens–Johnson syndrome diagnosed in a 49-year-old patient, with a focus on the clinical course, diagnostic challenges, and therapeutic approach. Materials and Methods: A clinical, laboratory, and anamnesis-based analysis was conducted on a 49- year-old patient hospitalized with signs of a toxic-allergic cutaneous reaction. Methods included clinical observation, assessment of skin and mucosal involvement severity, laboratory monitoring, and evaluation of therapeutic effectiveness. Results: Discontinuation of the drug and initiation of intensive combination therapy led to clinical stabilization and symptom regression. The patient was discharged on the 21st day with an improvement in overall condition, with epithelialization and regeneration of the skin process, residual areas of depigmentation and hyperpigmentation, mild peeling, and skin dryness. Discussion: Stevens–Johnson syndrome (SJS) is a rare, severe adverse drug reaction, most often triggered by medications such as antibiotics and anticonvulsants. Although magnesium sulfate is considered safe and is widely used in clinical practice, the presented case demonstrates the possibility of developing a severe toxic-allergic skin reaction even when the drug is administered in therapeutic doses. Conclusion: This clinical case highlights the importance of careful drug history assessment, timely diagnosis, and immediate initiation of therapy in suspected cases of severe drug-induced cutaneous reactions. Diagnosis should primarily be based on the patient’s complaints, medical history, allergy history, physical examination findings, and the results of clinical and laboratory investigations.